Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-19
2011-07-19
Stoica, Elly-Gerald (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S134100, C424S185100, C424S192100, C514S009100, C435S069700
Reexamination Certificate
active
07982014
ABSTRACT:
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
REFERENCES:
patent: 5229501 (1993-07-01), Keifer et al.
patent: 5288855 (1994-02-01), Bergonzoni et al.
patent: 5474914 (1995-12-01), Spaete
patent: 5486462 (1996-01-01), Rutter et al.
patent: 5707632 (1998-01-01), Williams et al.
patent: 5750371 (1998-05-01), Senoo et al.
patent: 5767250 (1998-06-01), Spaete
patent: 5863888 (1999-01-01), Dionne et al.
patent: 6255454 (2001-07-01), Keifer et al.
patent: 6344546 (2002-02-01), Dionne et al.
patent: 6350593 (2002-02-01), Williams et al.
patent: 6355440 (2002-03-01), Williams et al.
patent: 6384191 (2002-05-01), Williams et al.
patent: 6517872 (2003-02-01), Yayon et al.
patent: 6656728 (2003-12-01), Kavanaugh et al.
patent: 6844168 (2005-01-01), Keifer et al.
patent: 7135311 (2006-11-01), David et al.
patent: 2004/0063910 (2004-04-01), Kavanaugh et al.
patent: 2004/0115768 (2004-06-01), Follstad
patent: 2005/0187150 (2005-08-01), Mohammadi et al.
patent: 2006/0286102 (2006-12-01), Jin et al.
patent: 2007/0248605 (2007-10-01), Hestir et al.
patent: 0 545 343 (1993-06-01), None
patent: WO 91/00916 (1991-01-01), None
patent: WO 91/11459 (1991-08-01), None
patent: WO 2004/110487 (2004-12-01), None
patent: WO 2005/113596 (2005-12-01), None
patent: WO 2006/113277 (2006-10-01), None
patent: WO 2007/059574 (2007-05-01), None
patent: WO 2008/065543 (2008-06-01), None
European Search Report, mailed Jun. 5, 2009, in European Application No. 09 075 061.3.
Examination Report, mailed Sep. 25, 2009, in European Application No. 09 075 061.3.
Reply to Examination Report, filed Feb. 25, 2010, in European Application No. 09 075 061.3.
Akimoto et al., “Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta” Am. J. Physiol. Cell Physiol., vol. 284, No. 2, 2003, pp. C371-C377.
Anderson et al., “Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand” Human Molecular Genetics, vol. 7, No. 9, 1998, pp. 1475-1483.
Auguste et al., “Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms” Cancer Research, vol. 61, Feb. 15, 2001, pp. 1717-1726.
Baker et al., “Metabolic control of recombinant proteinN-glycan processing in NSO and CHO cells” Biotechnology and Bioengineering, vol. 73, No. 3, May 5, 2001, pp. 188-202.
Ballinger et al., “Semirational design of a potent, artificial agonist of fibroblast growth factor receptors” Nature Biotechnology, vol. 17, Dec. 1999, pp. 1199-1204.
Bernard et al., “Fibroblast growth factor receptors as molecular targets in thyroid carcinoma” Endocrinology, vol. 10, Nov. 24, 2004, pp. 1-26 and 6 pgs. figures.
Celli et al., “Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning” The EMBO Journal, vol. 17, No. 6, Mar. 16, 1998, pp. 1642-1655.
Chellaiah et al., “Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules” J. Biol. Chem., vol. 274, No. 49, Dec. 3, 1999, pp. 34785-34794.
Cheon et al., “High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains” Proc. Natl. Acad. Sci., vol. 91, Feb. 1994, pp. 989-993.
Compagni et al., “Fibroblast growth factors are required for efficient tumor angiogenesis” Cancer Research, vol. 60, Dec. 15, 2000, pp. 7163-7169.
Couglin et al., “Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo” J. Biol. Chem., vol. 263, No. 2, Jan. 15, 1988, pp. 988-993.
Ezzat et al., “A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells” Biochem. Biophys. Res. Comm., vol. 287, No. 1, 2001, pp. 60-65.
Feige et al., “Glycosylation of the basic fibroblast growth factor receptor” J. Biol. Chem., vol. 263, No. 28, Oct. 5, 1988, pp. 14023-14029.
Gowardhan et al., “Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer” British Journal of Cancer, vol. 92, Jan. 18, 2005, pp. 320-327.
Grossman et al., “Expression of human thyrotropin in cell lines with different glycosylation patterns combined with mutagenesis of specific glycosylation sites” J. Biol. Chem., vol. 270, No. 49, Dec. 8, 1995, pp. 29378-29385.
Guillonneau et al., “Fibroblast growth factor (FGF) soluble receptor 1 acts as a natural inhibitor of FGF2 neurotrophic activity during retinal degeneration” Molecular Biology of the Cell, vol. 9, Oct. 1998, pp. 2785-2802.
Hanneken et al., “Identification of soluble forms of the fibroblast growth factor receptor in blood” Proc. Natl. Acad. Sci., vol. 91, Sep. 1994, pp. 9170-9174.
Hanneken et al., “Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid” Investigative Opthalmology & Visual Science, vol. 36, No. 6, May 1995, pp. 1192-1196.
Hanneken et al., “Structural characterization of the circulating soluble FGF receptors reveals multiple isoforms generated by secretion and ectodomain shedding” FEBS Letters, vol. 489, 2001, pp. 176-181.
Harding et al., “Role of VEGF, PDGF and FGF in glioblastoma progression as determined by soluble decoy receptor expression in preclinical models” Cell Genesys, Inc., Abstract No. 3030, presented at the AACR Annual Meeting, Apr. 16-20, 2005, 1 page.
Johnson et al., “Diverse forms of a receptor for acidic and basic fibroblast growth factors” Molecular and Cellular Biology, vol. 10, No. 9, Sep. 1990, pp. 4728-4736.
Johnson et al, “The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain” Molecular and Cellular Biology, vol. 11, No. 9, Sep. 1991, pp. 4627-4634.
Kan et al., “Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex” J. Biol. Chem., vol. 271, No. 42, Oct. 18, 1996, pp. 26143-26148.
Kaufman et al., “Characterization of ligand binding to immobilized biotinylated extracellular domains of three growth factor receptors” Anal. Biochem., vol. 211, No. 2, Jun. 1993, pp. 261-266.
Keifer et al., “Molecular cloning of a human basic fibroblast growth factor receptor cDNA and expression of a biologically active extracellular domain in a baculoviurs system” Growth Factors, vol. 5, 1991, pp. 115-127.
Kleeff et al., “Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines” Pancreas, vol. 28, No. 1, Jan. 2004, pp. 25-30.
Kwabi-Addo et al., “The role of fibroblast growth factors and their receptors in prostate cancer” Endocrine-Related Cancer, vol. 11, No. 4, Dec. 2004, pp. 709-724.
Lee et al., “Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor” Science, vol. 245, No. 4913, Jul. 7, 1989, pp. 57-60.
Levi et al., “Matrix metalloproteina
Bosch Elizabeth
Doberstein Stephen
Hestir Kevin
Hollenbaugh Diane
Lee Ernestine
Finnegan Henderson Farabow Garrett & Dunner LLP
Five Prime Therapeutics, Inc.
Stoica Elly-Gerald
LandOfFree
FGFR3-IIIc fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FGFR3-IIIc fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FGFR3-IIIc fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740530